AGE-SPECIFIC GENDER DIFFERENCES IN EARLY MORTALITY FOLLOWING ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION IN CHINA

Xin Zheng,1 Rachel P Dreyer,2 Shuang Hu,1 Erica S Spatz,2,3 Frederick A Masoudi,4,5 John A Spertus,6 Khurram Nasir,7 Xi Li,1 Jing Li,1 Sisi Wang,2,8 Harlan M Krumholz,2,3,9,10 Lixin Jiang,1 for the CHINA PEACE Collaborative Group

ABSTRACT
Objective To assess whether younger, but not older, women in China have higher in-hospital mortality following ST-Segment Elevation Myocardial Infarction (STEMI) compared with men, and whether this relationship varied over the last decade or across rural/urban areas.
Methods We analysed a nationally representative sample of 11 986 patients with STEMI from 162 Chinese hospitals in 2001, 2006 and 2011, in the China PEACE-Retrospective AMI Study and compared in-hospital mortality between women and men with gender–age interactions in multivariable models.
Results The overall in-hospital mortality rate was higher in women compared with men (17.2% vs 9.1%, p < 0.0001; unadjusted OR 2.07, 95% CI 1.85 to 2.33). The unadjusted OR for mortality in women, compared with men, was 2.20 (95% CI 1.59 to 3.04), 2.21 (95% CI 1.74 to 2.79), 1.37 (95% CI 1.15 to 1.65) and 1.25 (95% CI 0.97 to 1.63) for ages <60, 60–69, 70–79 and ≥80 years, respectively. After adjustment for patient characteristics, hospital characteristics and year of study, the OR for mortality comparing women with men was 1.69 (95% CI 1.01 to 2.83), 1.64 (95% CI 1.24 to 2.19), 1.15 (95% CI 0.90 to 1.46) and 0.82 (95% CI 0.60 to 1.11) for ages <60, 60–69, 70–79 and ≥80 years, respectively. The gender–age interaction for mortality was statistically significant (p = 0.009), even after adjustment for a wide range of confounders, and did not vary over time or across rural/urban areas.
Conclusions Among a Chinese population with STEMI, gender differences in early mortality were age-dependent and greatest in the younger groups <70 years of age.

INTRODUCTION
Several studies from high-income areas, including the USA, Canada and Europe, have demonstrated gender differences in mortality following acute myocardial infarction (AMI) that vary by age,1–8 with a higher risk of death in younger women compared with their male counterparts. For example, in a US study of patients hospitalised with AMI between 1994 and 1998, women aged ≤50 years had a more than twofold greater in-hospital mortality compared with similarly aged men,6 but this difference was not present in older patients. A remaining question is whether this gender–age interaction in AMI mortality, in which gender differences are greater in younger patients, exists in diverse populations and healthcare systems, especially in low-income and middle-income countries.

In China, home to one-fifth of the world’s women, there is a rising burden of cardiovascular disease.9 Moreover, as observed in the recently published China Patient-centered Evaluative Assessment of Cardiac Events (China PEACE)-Retrospective AMI Study of patients with ST-Segment Elevation Myocardial Infarction (STEMI), there was a fourfold increase in hospital admissions among both men and women over the last decade, with women persistently accounting for nearly 30% of all patients.10 In this growing population of women with AMI, it is critical to understand whether gender differences in survival among different age groups exist, especially as China prepares to embark on national efforts to improve the quality of AMI care.

Examining potential gender disparities in STEMI outcomes in China is important, as findings from Western countries may not be broadly applicable. Though prior studies from China have suggested higher rates of death in younger women after STEMI,11 these data are not contemporary and may not reflect the experience of average patients as they were based on clinical trial populations. Further investigation is needed to understand whether age-gender disparities exist among a nationally representative sample and whether differences in outcomes have changed over the last decade. Additionally, to inform future interventions, it is important to understand whether any differences observed can be explained by patient risk, hospital care management or the settings in which care is delivered.

Accordingly, we examined a nationally representative sample of patients with STEMI in the China PEACE-Retrospective AMI Study in 2001, 2006 and 2011. The objectives of this study were to (a) assess whether there is a significant gender–age interaction with in-hospital mortality among Chinese patients with STEMI; (b) identify factors that may explain this gender–age interaction and (c) determine whether this gender–age interaction has changed over time or varies across rural/urban areas. We hypothesised that younger, but not older,
Coronary artery disease

women with STEMI in China would have a higher risk of in-hospital mortality, compared with age-matched men. The findings of this study will assist in identifying vulnerable groups at risk for early mortality, identifying potential mediators of mortality differences, and stimulating quality improvement efforts to improve outcomes for younger women with STEMI.

METHODS

Data source and study population

The design of the China PEACE-Retrospective AMI Study has been previously described. In brief, we created a nationally representative sample of hospitalisations for AMI during 2001, 2006 and 2011 using a 2-stage random sampling design. Since hospital volumes and clinical capacities differ between urban and rural areas, as well as among the 3 official economic-geographic regions of China, we identified hospitals in 5 strata: Eastern-rural, Central-rural, Western-rural, Eastern-urban and Central/Western-urban regions. We then used systematic random sampling to sample cases with AMI, which were identified using International Classification of Diseases versions 9 and 10, when available, or through principle discharge diagnosis terms from the selected hospitals.

We included patients with STEMI (n=13 815), which was confirmed by discharge diagnosis and electrocardiogram results. For the purposes of the present analysis, patients who were transferred in (n=559), transferred out (n=1148) or discharged within 24 h of admission (n=122) were excluded. The final study cohort consisted of 11 986 patients (n=3574 women, 29.8%).

The Chinese government, which provided financial support for the study, had no role in the design or conduct of the study; in the collection, management, analysis and interpretation of the data; or in the preparation or approval of the manuscript. The central ethics committee of the China National Center for Cardiovascular Diseases approved this study. All collaborating hospitals accepted the central ethics approval except for 5 hospitals that obtained local approval by internal ethics committees. The study is registered at http://www.clinicaltrials.gov (NCT01624883).

Medical record review and variables

Data were collected via standardised central medical chart abstraction using standardised data definitions. Variables abstracted from the medical records of each hospital included patient-level characteristics, hospital-level characteristics, year of discharge, length of stay, and in-hospital outcomes. In-hospital mortality was defined as a composite of death during hospitalisation or withdrawal from treatment due to a terminal status at discharge. Withdrawal from treatment is common in China due to many patients’ families’ reluctance to die in the hospital. The Chinese government uses in-hospital death or withdrawal from treatment as an indicator of quality for hospitals. Composite complications included re-infarction, cardiogenic shock, cardiac arrest, congestive heart failure, and ischaemic stroke (for definitions, see online supplementary appendix). Major bleeding included any intracranial bleeding; or absolute drop of haemoglobin of at least 5 g/dL; or bleeding resulting in hypovolemic shock or fatal bleeding (bleeding that directly results in death within 7 days).

Statistical analysis

Based on the distribution of in-hospital mortality among women and men, as well as the cut-off of age used in a previous landmark manuscript, we stratified the study sample into 4 pre-specified age groups (<60, 60–69, 70–79, and ≥80 years). Continuous variables were expressed as mean±SD and compared using unpaired t test. Using χ² tests, we compared cardiovascular risk factors, medical history, clinical characteristics at admission, treatment during hospitalisation, in-hospital outcomes, hospital characteristics, and year of discharge between women and men in each age group. Crude ORs with 95% CIs for women versus men were reported.

We used multivariable logistic regression models to calculate adjusted OR and 95% CI for in-hospital mortality in the overall population and within each age group, and to determine whether there was a significant interaction between gender and age with respect to in-hospital mortality. Candidate variables for inclusion in the multivariable models included cardiovascular risk factors, medical history, clinical characteristics at admission, treatment during hospitalisation, length of stay, hospital characteristics, and year of discharge. The final models included only those variables that differed significantly between women and men (p<0.05). We also assessed 2 three-way interaction terms: (1) gender×age×year and (2) gender×age×rural/urban to assess whether age-dependent gender differences in in-hospital mortality changed either (a) over time or (b) across rural/urban areas. All comparisons were 2-tailed, with a p value<0.05 considered statistically significant. Statistical analyses were performed using SAS software (V9.2, SAS Institute, Cary, North Carolina, USA) and R software (V3.0.2).

RESULTS

Baseline characteristics

Women presenting with STEMI were significantly older than men with STEMI (69.8±10.4 years vs 62.6±12.6 years, respectively, p<0.001). Younger women (<60 years) were more likely to have hypertension (OR=1.84; 95% CI 1.54 to 2.20), diabetes (OR=2.06; 95% CI 1.68 to 2.54) and were less likely to smoke (OR=0.09; 95% CI 0.07 to 0.12) compared with men. Women over the age of 60 years were also less likely to have had a prior AMI. Differences in these cardiovascular risk factors were attenuated in the older age groups (table 1).

Clinical characteristics at presentation also differed between women and men with significant variations by age group. Younger women (<60 years) were more likely than similarly aged men to have symptoms lasting >24 h before hospital admission, while older women (aged 60–69 and 70–79 years) were less likely to have experienced chest discomfort compared with men. Younger women (<60 years) had higher systolic blood pressures and higher heart rates (≥100 bpm), but fewer cardiac arrests at presentation compared with similarly aged men and with older women. Additionally, younger women had worse renal function (glomerular filtration rate <60 mL/min) and higher low-density lipoprotein cholesterol levels than their male peers at presentation. Of note, women <60 years of age were more likely to live in rural than in urban areas (table 1).

In-hospital treatments also varied by gender and age. Younger women (<60 years) were less likely to receive clopidogrel within 24 h of admission (OR=0.80; 95% CI 0.67 to 0.95) or any statin therapy during hospitalisation (OR=0.79; 95% CI 0.65 to 0.96). Women aged 60–69 years were also less likely to receive aspirin, clopidogrel and β-blockers within 24 h of admission and statins during hospitalisation. With respect to reperfusion strategies, women aged <80 years were less likely to receive any reperfusion, especially those <60 years (OR=0.68; 95% CI 0.56 to 0.81), including less primary percutaneous coronary intervention (PCI) within 24 h (OR=0.54; 95% CI 0.40 to 0.73), compared with similarly aged men. All
women were less likely to undergo cardiac catheterisation and those 60–69 and 70–79 years of age were less likely to undergo PCI or any revascularisation compared with their male peers (table 2).

Finally, women <60 years of age had higher rates of any composite complications than men, while there were no significant gender differences among other age groups. The rate of major bleeding was similar by gender in each age group (table 2).
The overall in-hospital mortality rate was higher in women than in men (17.2% vs 9.1%, p < 0.0001; unadjusted OR 2.07, 95% CI 1.85 to 2.33). In-hospital mortality following STEMI increased with age for both genders. Among younger women (<60 years), the in-hospital mortality rate was twofold higher compared with men (9.4% vs 4.5%, p < 0.0001; unadjusted OR = 2.20, 95% CI 1.59 to 3.04), and similarly for women aged 60–69 years (15.2% vs 7.5%, p < 0.0001; unadjusted OR = 2.21, 95% CI 1.74 to 2.79). A higher risk of death was also observed among older women 70–79 years of age (18.6% vs 14.3%, p = 0.0006; unadjusted OR = 1.37, 95% CI 1.15 to 1.65), but there was no difference in the risk of death in women over 80 years of age (24.8% vs 20.8%, p = 0.09; unadjusted OR = 1.25, 95% CI 0.97 to 1.63). When mortality rates were examined by age, a gender–age interaction was observed (p = 0.0007) (Figure 1). In addition, we also found that women aged 60–69, as well as ≥80 years of age, were more likely to die within 24 h of admission compared with their male peers (Table 2).

The gender–age–year interaction was not significant (p = 0.38), indicating that the gender–age interaction did not change over time (Figure 2). In addition, there was no gender–age–area (rural/urban) interaction (p = 0.95), suggesting equally poor outcomes in women regardless of whether they were treated in urban or in rural hospitals.

### Table 2 Unadjusted OR for treatments, testing and in-hospital outcomes comparing women with men according to age

<table>
<thead>
<tr>
<th></th>
<th>All patients</th>
<th>Age group, year</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Women (n=3574)</td>
<td>Men (n=8412)</td>
</tr>
<tr>
<td></td>
<td>&lt;60 (n=3914)</td>
<td>60–69 (n=3213)</td>
</tr>
<tr>
<td><strong>Acute medications</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aspirin ≤24 h</td>
<td>83.9</td>
<td>87.5</td>
</tr>
<tr>
<td>Clopidogrel ≤24 h</td>
<td>51.5</td>
<td>56.6</td>
</tr>
<tr>
<td>β-Blocker ≤24 h</td>
<td>43.8</td>
<td>48.5</td>
</tr>
<tr>
<td>ACE-I/ARB</td>
<td>60.2</td>
<td>63.8</td>
</tr>
<tr>
<td>Statin</td>
<td>73.0</td>
<td>75.2</td>
</tr>
<tr>
<td><strong>Reperfusion therapies ≤24 h</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Primary PCI</td>
<td>8.5</td>
<td>12.8</td>
</tr>
<tr>
<td>Fibrinolytic therapy</td>
<td>18.9</td>
<td>24.7</td>
</tr>
<tr>
<td>Any reperfusion</td>
<td>27.4</td>
<td>37.5</td>
</tr>
<tr>
<td><strong>Staged procedures</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardiac catheterisation</td>
<td>18.8</td>
<td>28.8</td>
</tr>
<tr>
<td>PCI</td>
<td>8.6</td>
<td>13.9</td>
</tr>
<tr>
<td>CABG</td>
<td>0.34</td>
<td>0.61</td>
</tr>
<tr>
<td>Any revascularisation</td>
<td>8.9</td>
<td>14.4</td>
</tr>
<tr>
<td><strong>Testing</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Troponin</td>
<td>48.9</td>
<td>49.9</td>
</tr>
<tr>
<td>Echocardiogram</td>
<td>46.1</td>
<td>52.6</td>
</tr>
<tr>
<td><strong>In-hospital outcomes</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Death†</td>
<td>12.5</td>
<td>6.7</td>
</tr>
<tr>
<td>Death† + withdrawal from treatment</td>
<td>17.2</td>
<td>9.1</td>
</tr>
<tr>
<td>Death within 24 h</td>
<td>5.5</td>
<td>2.9</td>
</tr>
<tr>
<td>Composite complications</td>
<td>15.3</td>
<td>11.8</td>
</tr>
<tr>
<td>Major bleeding</td>
<td>0.8</td>
<td>1.0</td>
</tr>
<tr>
<td><strong>Length of stay (days)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;8</td>
<td>29.5</td>
<td>22.7</td>
</tr>
<tr>
<td>8–11</td>
<td>20.9</td>
<td>24.0</td>
</tr>
<tr>
<td>12–15</td>
<td>21.4</td>
<td>23.4</td>
</tr>
<tr>
<td>≥16</td>
<td>28.2</td>
<td>29.8</td>
</tr>
</tbody>
</table>

*The OR is for the comparison of women with men.
†The OR is significant between women and men.
‡During hospitalisation.
ACE-I/ARB, angiotensin converting enzyme inhibitor/angiotensin receptor blocker; Composite complication: recurrent MI, cardiac shock, cardiac arrest, congestive heart failure and ischaemic stroke; CABG, coronary artery bypass graft; PCI, percutaneous coronary intervention.

---

**Figure 1** In-hospital mortality rate following ST-segment elevation myocardial infarction among women and men by age. The interaction between gender and age was statistically significant (p = 0.0007).
Multivariable-adjusted in-hospital mortality

In the multivariable model, even after adjustment for differences in patient characteristics, hospital characteristics, length of stay and year of discharge, the interaction between gender and age for in-hospital mortality remained significant (p=0.0012). The adjusted OR for in-hospital mortality, comparing women with men, was 1.69 (95% CI 1.01 to 2.83), 1.64 (95% CI 1.24 to 2.19), 1.15 (95% CI 0.90 to 1.46) and 0.82 (95% CI 0.60 to 1.11) for age <60 years, age 60–69, age 70–79 and age ≥80 years, respectively. Women <70 years of age had an excess risk of mortality as compared with men; while there was no significant gender difference among patients ≥70 years old (figure 3).

DISCUSSION

In this first study to investigate gender differences in in-hospital mortality across the spectrum of age in a nationally representative population of patients with STEMI in China, women younger than 70 years had a >60% increased odds of dying in the hospital, compared with similarly aged men. This pattern of mortality was observed after accounting for differences in a wide range of patient and hospital characteristics. These mortality differences persisted despite changes in cardiovascular epidemiology over the last decade and differences in healthcare resources across rural and urban settings.

Our findings extend the previous literature, primarily based on US patients, by showing significant gender differences in outcomes by age in China, a low-income and middle-income country with a large, potentially very different patient population and with different challenges and inequalities in healthcare services than more highly resourced Western countries. Some differences between the USA and China do exist, however, in the USA, there was a twofold higher risk of death in the sub-group of women aged <50 years, while in the current study of Chinese patients the increased risk of death was observed among older patients as well, up to 70 years of age. The reasons for this international difference are unknown and worthy of further investigation. Based on the current data, and on our knowledge of gender differences in coronary heart disease.

Figure 2 Unadjusted risk of in-hospital mortality comparing women with men according to age (2001, 2006 and 2011). The interaction among gender, age and year was not statistically significant (p=0.38).

Figure 3 Unadjusted and adjusted risk of in-hospital mortality comparing women with men by age. In the unadjusted data (left panel), the interaction between gender and age was statistically significant (p=0.0009). After adjustment for differences in patient characteristics, hospital characteristics and year of discharge (right panel), the interaction between gender and age remained statistically significant (p=0.0012).
and adverse outcomes following these events. In addition to and portend a higher risk of premature cardiovascular events vascular risk factors outweigh the protective effects of oestrogen middle age may represent a distinct phenotype, whereby cardio-

mechanisms, coagulability states, hormonal status, and coron-
graphic characteristics, may be involved. Moreover, biological this study, such as door-to-balloon time and coronary angio-

interaction, suggesting the contribution of alternative mechan-

Other possible explanations for the poor prognosis observed among younger women include a lack of awareness of symp-
toms, under-recognition at presentation and lower application of evidence-based medication and timely reperfusion therapy. In our study, women aged <60 years had a longer time from symptom onset to admission compared with other age groups, which may explain the less frequent use of early reperfusion and, ultimately, the higher risk of mortality in this age group. Delayed hospital presentation in younger women may be due to atypical symptom onset of AMI, which can also result in delayed detection of the condition after the patients arrive at hospital. In addition, less use of evidence-based therapies at admission may contribute to the higher mortality in younger women. Of note, the US studies have found that the gender difference in evidence-based treatment did not adequately account for the observed mortality disparity. However, in developing countries, addressing the aforementioned disparities in disease awareness, recognition and timely administration of evidence-

ated differences in evidence-based treatment did not adequately account for the observed mortality disparity. However, in developing countries, addressing the aforementioned disparities in disease awareness, recognition and timely administration of evidence-

What is already known on this subject? In studies from high-income areas such as the USA, Canada and Europe, gender differences in mortality following acute myocardial infarction (AMI) vary by age, with a higher risk of death observed in younger women compared with their male counterparts.

What might this study add? In China, a low-income and middle-income country with a diverse population and healthcare system, we also observed significantly higher in-hospital mortality among younger women compared with men, following hospitalisation for ST-Segment Elevation Myocardial Infarction (STEMI). This pattern persisted after adjusting for a wide range of confounders, including patient- and hospital-level characteristics, and did not vary over time or across rural/urban areas. The gender differences were greatest in the younger groups <70 years of age.

How might this impact on clinical practice? These findings indicate that the higher risk of death among younger women following AMI is a global health problem, found in high-income countries and in developing nations such as China. The findings identify young women as a vulnerable group for in-hospital mortality after STEMI and underscore the need for interventions to address this disparity.
Author affiliations
1National Clinical Research Center of Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fujwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People’s Republic of China
2Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, Connecticut, USA
3Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA
4Division of Cardiology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA
5Colorado Cardiovascular Outcomes Research Consortium, Denver, Colorado, USA
6Health Outcomes Research, Saint Luke’s Mid America Heart Institute/University of Missouri-Kansas City (JAS). Kansas City, Missouri, USA
7Center for Wellness & Prevention Research and Miami Cardiovascular Institute, Baptist Health South Florida, Miami, Florida, USA
8Yale School of Public Health, New Haven, Connecticut, USA
9Robert Wood Johnson Foundation Clinical Scholars Program, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA
10Department of Health Policy and Management, Yale School of Public Health, New Haven, Connecticut, USA

Acknowledgements We appreciate the multiple contributions made by study teams at the China Oxford Centre for International Health Research and the Yale-New Haven Hospital Center for Outcomes Research and Evaluation in the realms of study design and operations, particularly the data collection by Yi Pi, Jianmin Liu, Wuhanbilige Hundei, Haibo Zhang, Lijuan Zhan, Lihua Zhang, Xue Du and Wenchi Guan. We appreciate the advice by Yongfei Wang, Zhenqiu Lin, Shuxia Li and Haiqin Lin.

Contributors HMK and LJ conceived the China PEACE study and take responsibility for all aspects of it. JL, XL, FAM, JAS, HMK and LJ designed the study. XZ wrote the first draft of the article, with further contributions from RPD, ESS, FAM, JAS, KN, XL, JW, HMK and LJ. SH did statistical analysis, with support from XL. All authors interpreted data and approved the last draft of the article.

Funding This project was partly supported by the Research Special Fund for Public Welfare Industry of Health (201102025) from National Health and Family Planning Commission of China. Professor Krumholz is supported by grant U01 HL105270-05 (Center for Cardiovascular Outcomes Research at Yale University) from the National Heart, Lung, and Blood Institute.

Competing interests None.

Ethics approval The Central Ethics Committee of the China National Center for Cardiovascular Diseases.

Provenance and peer review Not commissioned; externally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

REFERENCES